5 Key Takeaways
-
1
Preservative-free bimatoprost 0.01% gel, marketed as Zolymbus, aims to lower intraocular pressure (IOP) while minimizing ocular surface irritation.
-
2
The gel formulation utilizes mucoadhesive properties to enhance drug absorption and maintain contact with the cornea.
-
3
This new formulation avoids benzalkonium chloride (BAK), which is known to irritate the ocular surface in glaucoma patients.
-
4
Pharmacokinetic studies show that the preservative-free gel achieves intraocular concentrations comparable to bimatoprost 0.03%.
-
5
Zolymbus is expected to be available in the US market by the end of 2026, enhancing glaucoma treatment options.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







